

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/751,702
		Filing Date	1/5/04
		First Named Inventor	Tuomanen
		Group Art Unit	1645
Examiner Name	N. Minnifield		
Sheet 1 of 1	Attorney Docket Number	044158/273011	

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
/NMM/	33	US-6,573,082	06-03-2003	CHOI <i>et al.</i>	
	34	US-6,500,613	12-31-2002	BRILES <i>et al.</i>	
	35	US-6,784,164	08-31-2004	MASCLE <i>et al.</i>	
	36	US-6,698,369	02-2004	KOENIG <i>et al.</i>	
	37	US-2002/0061545	05-23-2003	CHOI <i>et al.</i>	
	38	US-2003/0059438	03-27-2003	BRILES <i>et al.</i>	
	39	US-2003/0091577	05-15-2003	GILBERT <i>et al.</i>	
	40	US-2003/0096950	05-22-2003	TUOMANEN <i>et al.</i>	
/NMM/	41	US-2003/0138447	07-24-2003	WIZEMANN <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
-------------------	----------	--	--------------------------------	--	--	--

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	English Language Translation Attached
/NMM/	42	BROOKS-WLATER, "The <i>pspC</i> Gene of <i>Streptococcus pneumoniae</i> Encodes a Polymorphic Protein, PspC, Which Elicits Cross-Reactive Antibodies to PspA and Provides Immunity to Pneumococcal Bacteremia," <i>Infection and Immunity</i> , 1999, pp. 6533-6542, Vol. 67(12).	
/NMM/	43	CHENG, Q., <i>et al.</i> , "Novel Purification Scheme and Functions for a C3-Binding Protein From <i>Streptococcus pneumoniae</i> ," <i>Biochemistry</i> , 2000, pp. 5450-5457, Vol. 39.	
/NMM/	44	HOSKINS, J., <i>et al.</i> , "Genome of the Bacterium <i>Streptococcus pneumoniae</i> Strain R6," <i>J. of Bacteriology</i> , 2001, pp. 5709-5717, Vol. 183(19).	
/NMM/	45	IANNELLI, F., <i>et al.</i> , "Allelic Variation in the Highly Polymorphic Locus <i>pspC</i> of <i>Streptococcus pneumoniae</i> ," <i>Gene</i> , 2002, pp. 63-71, Vol. 284.	
/NMM/	46	TETTELIN, H., <i>et al.</i> , "Complete Genome Sequence of A Virulent Isolate of <i>Streptococcus pneumoniae</i> ," <i>Science</i> , 2001, pp. 498-506, Vol. 293.	

Examiner Signature	/N. M. Minnifield/ (04/10/2007)	Date Considered	04/10/2007
--------------------	---------------------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
LEGAL02/30221320v1

FILED 01-05-04

COPY

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known				
				Application Number	To be Assigned 10/751702			
				Filing Date	Concurrently Herewith 01-05-04			
				First Named Inventor	Tuomanen			
				Group Art Unit	To be Assigned			
Sheet 1 of 2	Examiner Name	To be Assigned						
Attorney Docket Number		044158/273011						
U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Page, Columns, Lines, Where Relevant Passages of Relevant Figures Appear		
/NMM/	1	US-4,925,673		STEINER <i>et al.</i>	05-15-1990			
	2	US-5,013,556		WOODLE <i>et al.</i>	05-07-1991			
	3	US-5,284,656		PLATZ <i>et al.</i>	02-08-1994			
	4	US-5,451,569		WONG <i>et al.</i>	09-15-1995			
	5	US-6,245,335		MASURE <i>et al.</i>	06-12-2001			
	6	US-6,291,654		HOSTETTER <i>et al.</i>	09-18-2001			
	7	US-6,420,135		KUNSCH <i>et al.</i>	07-16-2002			
/NMM/	8	US-6,503,511		WIZEMANN <i>et al.</i>	01-07-2003			
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Office ³	Number ⁴	Kind Code (if known) ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/NMM/	9	EP	401,384		ISHIKAWA, R.	03-13-1996		
	10	WO	97/41151		MASURE, H., <i>et al.</i>	11-06-1997	1-53	
	11	WO	97/09994		BRILES, D., <i>et al.</i>	03-20-1997	1-28, 40, 53	
	12	WO	98/21337		HOSTETTER, M., <i>et al.</i>	05-22-1998	1-53	
	13	WO	98/18930		KUNSCH, C., <i>et al.</i>	05-07-1998	1-53	
	14	WO	99/51187		TUOMANEN, E., <i>et al.</i>	10-14-1999	1-53	
/NMM/	15	WO	99/51266		WIZEMANN, T., <i>et al.</i>	10-14-1999	1-53	
OTHER DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.						T
/NMM/	16	ADJEL <i>et al.</i> , "Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers" <i>Pharma Res.</i> , 1990, pp. 565-569, Vol. 7.						

/NMM/ 04/10/2007 (04/10/2007)

¹ Unique citation designation number.² See attached Kinds of U.S. Patent Documents.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

COPY

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	To be Assigned 10/79/702	
				Filing Date	Concurrently Herewith 01-05-04	
				First Named Inventor	Tuomanen	
				Group Art Unit	To be Assigned 1645	
				Examiner Name	To be Assigned MINNIFIELD	
Sheet	2	of	2	Attorney Docket Number	044158/273011	
OTHER DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.				
/NMM/ ↓ /NMM/	17	CUNDELL <i>et al.</i> , "Receptor specificity of adherence of <i>Streptococcus pneumoniae</i> to human type II pneumocytes and vascular endothelial cells in vitro," <i>Micro Pathog.</i> , 1994, pp. 361-374, Vol. 17.				
	18	CUNDELL <i>et al.</i> , "Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet activating factor," <i>Nature</i> , 1995, pp. 435-438, Vol. 377.				
	19	HAMMERSCHMIDT <i>et al.</i> , "SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component," <i>Mol. Microbiol.</i> , 1997, pp. 1113-1124, Vol. 25.				
	20	IDANPAAN-HEIKKELA I., <i>et al.</i> , "Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia," <i>J. Infect. Dis.</i> , 1997, pp. 704-712, Vol. 176.				
	21	LANGER, "New methods of drug delivery," <i>Science</i> , pp. 1527-1533, Vol. 249.				
	22	MALIK <i>et al.</i> , "Polyethylene glycol (PEG) modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity," <i>Exp. Hematol.</i> , 1992, pp. 1028-1035, Vol. 20.				
	23	MCDANIEL <i>et al.</i> , "Molecular localization of variable and conserved regions of <i>pspA</i> and identification of additional <i>pspA</i> homologous sequences in <i>Streptococcus pneumoniae</i> ," <i>Microb. Pathog.</i> , 1992, pp. 261-269, Vol. 13.				
	24	NEWMARK <i>et al.</i> , " <i>J. Appl. Biochem.</i> , 1982, pp. 185-189, Vol. 4.				
	25	REMINGTON'S PHARMACEUTICAL SCIENCES, 18 th ed., 1990, Chap. 89, Mack Publishing Co., Easton, PA.				
	26	RONDA <i>et al.</i> , "Biological role of the pneumococcal amidase. Cloning of the <i>lytA</i> gene in <i>Streptococcus pneumoniae</i> ," <i>Eur. J. Biochem.</i> , 1987, pp. 621-624, Vol. 164.				
	27	ROSENOW <i>et al.</i> , "Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of <i>Streptococcus pneumoniae</i> ," <i>Mol. Microbiol.</i> , 1997, p. 819, Vol. 25.				
	28	SHAPIRO <i>et al.</i> , "The protective efficacy of polyvalent pneumococcal polysaccharide vaccine," <i>NJEM</i> , 1991, p. 1453, Vol. 325.				
	29	TUOMANEN <i>et al.</i> , "Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria," <i>Rev. Infect. Dis.</i> , 1986, p. 279, Vol. 8, Suppl. 3.				
	30	TUOMANEN <i>et al.</i> , "Microbiological and clinical significance of a new property of defective lysis in clinical strains of pneumococci," <i>J. Infect. Dis.</i> , 1988, pp. 36-43, Vol. 158.				
	31	TUOMANEN <i>et al.</i> , "Pathogenesis of pneumococcal infection," <i>NEJM</i> , 1995, pp. 1280, Vol. 322.				
	32	WEARLY, <i>Crit. Rev. in Their Drug Carrier System</i> , 1991, pp. 333, Vol. 8.				
	Examiner Signature		/N. M. Minnifield/ (04/10/2007)		Date Considered	04/10/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FOR SCANNING ONLY

Substitute for form 1449A/PTO				Complete if Known				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number		To be Assigned 10/751702		
				Filing Date		Concurrently Herewith		
				First Named Inventor		Tuomanen		
				Group Art Unit		To be Assigned 1645		
				Examiner Name		To be Assigned MINNFIELD		
Sheet	1	of	2	Attorney Docket Number		044158/273011		
U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear		
NMM	1	US-4,925,673		STEINER <i>et al.</i>	05-18-1990			
NMM	2	US-5,013,556		WOODS <i>et al.</i>	08-07-1991			
NMM	3	US-5,284,656		PLATE <i>et al.</i>	02-08-1994			
NMM	4	US-5,451,569		WONG <i>et al.</i>	09-15-1995			
NMM	5	US-6,245,335		MASURE <i>et al.</i>	06-12-2001			
NMM	6	US-6,291,654		HOSTETTER <i>et al.</i>	09-18-2001			
NMM	7	US-6,420,135		KUNSCH <i>et al.</i>	07-16-2002			
NMM	8	US-6,503,511		WIZEMANN <i>et al.</i>	01-07-2003			
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
NMM	9	EP	401,384		ISHIKAWA, R.	03-13-1996		
NMM	10	WO	97/4115		MASURE, H., <i>et al.</i>	11-06-1997	1-53	
NMM	11	WO	97/09994		BRILES, D., <i>et al.</i>	03-20-1997	1-28, 40, 53	
NMM	12	WO	98/21337		HOSTETTER, M., <i>et al.</i>	05-21-1998	1-53	
NMM	13	WO	98/18970		KUNSCH, C., <i>et al.</i>	05-07-1998	1-53	
NMM	14	WO	99/51187		TUOMANEN, E., <i>et al.</i>	10-14-1999	1-53	
NMM	15	WO	99/51266		WIZEMANN, T., <i>et al.</i>	10-14-1999	1-53	
OTHER DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T
	16	ADJEL <i>et al.</i> , "Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers," <i>Pharma Res.</i> , 1990, pp. 565-569, Vol. 7.						

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

FOR SCANNING ONLY

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	To be Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Tuomanen
				Group Art Unit	To be Assigned
				Examiner Name	To be Assigned
Sheet	2	of	2	Attorney Docket Number	044158/273011
OTHER DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	17	CUNDELL <i>et al.</i> , "Receptor specificity of adherence of <i>Streptococcus pneumoniae</i> to human type-II pneumocytes and vascular endothelial cells in vitro," <i>Micro Pathog.</i> , 1994, pp. 361-374, Vol. 17.			
	18	CUNDELL <i>et al.</i> , "Streptococcus pneumoniae adheres to activated human cells by the receptor for platelet-activating factor," <i>Nature</i> , 1995, pp. 435-438, Vol. 375.			
	19	HAMMERSCHMIDT <i>et al.</i> , "SpaA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component," <i>Mol. Microbiol.</i> , 1997, pp. 1113-1124, Vol. 25.			
	20	IDANPAAN-HEIKKELA I., <i>et al.</i> , "Polysaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia," <i>J. Infect. Dis.</i> , 1997, pp. 704-712, Vol. 176.			
	21	LANGER, "New methods of drug delivery," <i>Science</i> , pp. 1527-1533, Vol. 249.			
	22	MALIK <i>et al.</i> , "Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity," <i>Exp. Hematol.</i> , 1992, pp. 1028-1035, Vol. 20.			
	23	MCDANIEL <i>et al.</i> , "Molecular localization of variable and conserved regions of <i>pspA</i> and identification of additional <i>pspA</i> homologous sequences in <i>Streptococcus pneumoniae</i> ," <i>Microb. Pathog.</i> , 1992, pp. 261-269, Vol. 13.			
	24	NEWMARK <i>et al.</i> , "J. Appl. Biochem.", 1982, pp. 185-189, Vol. 4.			
	25	REMINGTON'S PHARMACEUTICAL SCIENCES, 18 th ed., 1990, Chap. 89, Mack Publishing Co., Easton, PA.			
	26	RONDI <i>et al.</i> , "Biological role of the pneumococcal amidase. Cloning of the <i>psaA</i> gene in <i>Streptococcus pneumoniae</i> ," <i>Eur. J. Biochem.</i> , 1987, pp. 621-624, Vol. 164.			
	27	ROSENOW <i>et al.</i> , "Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of <i>Streptococcus pneumoniae</i> ," <i>Mol. Microbiol.</i> , 1997, p. 819, Vol. 25.			
	28	SHAPIRO <i>et al.</i> , "The protective efficacy of polyvalent pneumococcal polysaccharide vaccine," <i>NJEM</i> , 1991, p. 1453, Vol. 325.			
	29	TUOMANEN <i>et al.</i> , "Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria," <i>Rev. Infect. Dis.</i> , 1986, p. 279, Vol. 8, Suppl. 3.			
	30	TUOMANEN <i>et al.</i> , "Microbiological and clinical significance of a new property of defective lysis in clinical strains of pneumococci," <i>J. Infect. Dis.</i> , 1988, pp. 36-43, Vol. 158.			
	31	TUOMANEN <i>et al.</i> , "Pathogenesis of pneumococcal infection," <i>NEJM</i> , 1995, pp. 1280, Vol. 322.			
	32	WEARLY, <i>Crit. Rev. in Their Drug Carrier System</i> , 1991, pp. 333, Vol. 8.			
Examiner Signature	/N. M. Minnifield/ (09/26/2006)			Date Considered	09/26/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.